High numbers of CD95+ CD8+ tumor infiltrating lymphocytes have previously been demonstrated to have predictive value in breast cancer patients [34] and an enhanced frequency of CD95+ T cells in blood of stage IV melanoma patients has been reported to associate with clinical response upon anti-PD-1 treatment [22]. This evidence concerns the gene CD8A and breast carcinoma.